WO2024184812 - ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
National phase entry:
Publication Number
WO/2024/184812
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052127
International Filing Date
05.03.2024
Title **
[English]
ANTI-CLDN6 ANTIBODIES AND METHODS OF USE
[French]
ANTICORPS ANTI-CLDN6 ET PROCÉDÉS D'UTILISATION
Applicants **
BEONE MEDICINES I GMBH
BEONE GUANGZHOU BIOLOGICS MANUFACTURING CO., LTD.
Inventors
LI, Dan
TANG, Xiaoyan
LEI, Ming
SHAO, Ting
Priority Data
PCT/CN2023/079815
06.03.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3402 | |
| EPO | Filing, Examination, Granting | 21419 | |
| Japan | Filing, Examination, Granting | 2816 | |
| South Korea | Filing, Examination, Granting | 3331 | |
| USA | Filing, Examination, Granting | 10990 |
Total:
41,958
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CLDN6, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.[French]
La présente divulgation concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient à la CLDN6 humaine, une composition pharmaceutique comprenant ledit anticorps ou des fragments de liaison à l'antigène de celui-ci, et l'utilisation de l'anticorps ou de fragments de liaison à l'antigène de celui-ci ou de la composition pour le traitement d'une maladie, telle que le cancer.